The genome-wide mRNA and transcription factor profiling showed that doxycycline inhibits oncogenic ER, Myc, E2F1, Wnt and SMAD2/3/4 pathways and activates NRF1/2, MTF1 and ATF6, stress-related pathways, and the p53-mediated tumour suppressor pathway. Here, TP53 is linked to neoplasm.